Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -106.27% is 101% below its 5-year average of -52.91%, near the low end of its 5-year range (-110.86%–-18.81%).
As of the fiscal period ended Tuesday, June 30, 2026. 2.84% below its 12-month average of -103.34%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -106.27%.
RETURN ON EQUITY (ROE)
-106.27%
RETURN ON EQUITY (ROE) AVG TTM
-103.34%
RETURN ON EQUITY (ROE) AVG 3Y
-70.05%
RETURN ON EQUITY (ROE) AVG 5Y
-52.91%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-2.84%
CURRENT VS 3Y AVG
-51.71%
CURRENT VS 5Y AVG
-100.86%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
-152.97%
vs the sector median at left
Lyell Immunopharma, Inc.
Market Cap
$210.98M
Return on Equity (ROE)
-106.27%
TTM Avg
-103.34%
3Y Avg
-70.05%
5Y Avg
-52.91%
Market Cap
$210.41M
Return on Equity (ROE)
-71.02%
TTM Avg
-15.82%
3Y Avg
-19.73%
5Y Avg
-5.35%
Market Cap
$209.91M
Return on Equity (ROE)
39.66%
TTM Avg
4.24%
3Y Avg
-15.88%
5Y Avg
-20.06%
Market Cap
$208.31M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.24M
Return on Equity (ROE)
19.38%
TTM Avg
20.63%
3Y Avg
-8.44%
5Y Avg
-40.10%
Market Cap
$214.46M
Return on Equity (ROE)
-36.64%
TTM Avg
6.57%
3Y Avg
27.96%
5Y Avg
27.96%
Market Cap
$207.27M
Return on Equity (ROE)
28.68%
TTM Avg
26.59%
3Y Avg
20.62%
5Y Avg
19.74%
Market Cap
$215.07M
Return on Equity (ROE)
21.24%
TTM Avg
17.52%
3Y Avg
32.51%
5Y Avg
46.01%
Market Cap
$205.80M
Return on Equity (ROE)
-43.64%
TTM Avg
-68.24%
3Y Avg
-59.30%
5Y Avg
-48.32%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | $210.98M | -106.27% | -103.34% | -70.05% | -52.91% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | -71.02% | -15.82% | -19.73% | -5.35% |
| Compugen Ltd. (CGEN)vs › | $209.91M | 39.66% | 4.24% | -15.88% | -20.06% |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 19.38% | 20.63% | -8.44% | -40.10% |
| Sionna Therapeutics, Inc. (SION)vs › | $214.46M | -36.64% | 6.57% | 27.96% | 27.96% |
| Pro-Dex, Inc. (PDEX)vs › | $207.27M | 28.68% | 26.59% | 20.62% | 19.74% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | 21.24% | 17.52% | 32.51% | 46.01% |
| Whitehawk Therapeutics Inc (WHWK)vs › | $205.80M | -43.64% | -68.24% | -59.30% | -48.32% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | -45.23% | -120.85% | -88.04% | -69.68% |
ROE
-106.3%
ROA
-79.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -106.27% |
| 2026-03-31 | -90.04% |
| 2025-12-31 | -110.57% |
| 2025-09-30 | -98.95% |
| 2025-06-30 | -110.86% |
| 2025-03-31 | -99.41% |
| 2024-12-31 | -89.60% |
| 2024-09-30 | -38.44% |
| 2024-06-30 | -37.12% |
| 2024-03-31 | -37.86% |
| 2023-12-31 | -35.82% |
| 2023-09-30 | -27.25% |
| 2023-06-30 | -28.43% |
| 2023-03-31 | -23.21% |
| 2022-12-31 | -21.98% |
| 2022-09-30 | -31.51% |
| 2022-06-30 | -27.31% |
| 2022-03-31 | -29.88% |
| 2021-12-31 | -26.91% |
| 2021-09-30 | -20.82% |
| 2021-06-30 | -18.81% |
| 2021-03-31 | -34.02% |
| 2020-12-31 | -28.46% |
